The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Open accessAbstract
Coffee and caffeine are speculated to be associated with the reduced risk of Parkinson’s disease (PD). The present study aimed to investigate the disease-modifying potential of caffeine on PD, either for healthy people or patients, through a meta-analysis. The electronic databases were searched using terms related to PD and coffee and caffeinated food products. Articles were included only upon fulfillment of clear diagnostic criteria for PD and details regarding their caffeine content. Reference lists of relevant articles were reviewed to identify eligible studies not shortlisted using these terms. In total, the present study enrolled 13 studies, nine were categorized into a healthy cohort and the rest into a PD cohort. The individuals in the healthy cohort with regular caffeine consumption had a significantly lower risk of PD during follow-up evaluation (hazard ratio (HR) = 0.797, 95% CI = 0.748–0.849, p < 0.001). The outcomes of disease progression in PD cohorts included dyskinesia, motor fluctuation, symptom onset, and levodopa initiation. Individuals consuming caffeine presented a significantly lower rate of PD progression (HR = 0.834, 95% CI = 0.707–0.984, p = 0.03). In conclusion, caffeine modified disease risk and progression in PD, among both healthy individuals or those with PD. Potential biological benefits, such as those obtained from adenosine 2A receptor antagonism, may require further investigation for designing new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“that have been suggested to underlie the decrease in PD risk associated with coffee consumption [218,219].”
From Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis (2020) · cites this paper as [219]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 1×
“Caffeine is an adenosine A2A receptor antagonist [8].”
BackgroundLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821 · cited 1×
“However, responses to one-night washout are variable, and the effect of levodopa may last for 2 weeks [43].”
BackgroundEpidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199 · cited 1×
“Risk factors for PD include genetic mutations, environmental toxins, and lifestyle [1].”
BackgroundA Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901 · cited 1×
“Moreover, if the intervention itself causes certain symptomatic effects in conjunction, similar to rasagiline or caffeine, it would be challenging to distinguish between disease modification and symptomatic effect [44].”
BackgroundPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“[17] USA Health Professionals’ Follow-Up Study and Nurses’ Health Study (1976 and 1986/1994) 135,916 Semiquantitative food-frequency questionnaire (SFFQ) Caffeine was 137 mg per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of cola beverage, and 7 mg per serving of chocolate candy.”
BackgroundNeuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Cited by
Ikram, M. A., Park, T. J., Ali, T., & Kim, M. O. (2020) · Antioxidants · doi:10.3390/antiox9090902 · Cited by 170
Schiess, N., Cataldi, R., Okun, M. S., Fothergill‐Misbah, N., Dorsey, E. R., Bloem, B. R., Barretto, M., Bhidayasiri, R., Brown, R. J., Chishimba, L., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1783 · Cited by 158
Caffeine and Its Antioxidant Properties—It Is All about Dose and Source
Ősz, B.-E., Jîtcă, G., Ștefănescu, R., Puşcaş, A., Tero-Vescan, A., & Vari, C.-E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113074 · Cited by 177
Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis
Iriondo-DeHond, A., Uranga, J. A., del Castillo, M. D., & Abalo, R. (2020) · Nutrients · doi:10.3390/nu13010088 · Cited by 126
“As mentioned for caffeine, CA and CGA are coffee components with antioxidant properties and neuroprotective effects against dopaminergic neurotoxicity [216,217] that have been suggested to underlie the decrease in PD risk associated with coffee consumption [218,219].”
BackgroundThe Role of Diet and Dietary Patterns in Parkinson’s Disease
Knight, E., Geetha, T., Burnett, D. O., & Babu, J. R. (2022) · Nutrients · doi:10.3390/nu14214472 · Cited by 111
“A metaanalysis observed that caffeine consumption typically from coffee is inversely related to PD risk and progression [51].”
Background
Metadata
- Authors
- Hong, C. T., Chan, L., & Bai, C.-H.
- Affiliations
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University Hospital (TW)
- Corresponding author
- Chan, Lung
- Bai, Chyi-Huey
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-06-22
- Volume
- 12
- Issue
- 6
- Pages
- 1860
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7353179
- OpenAlex
- W3036886081
- Cited by
- 113
- References
- 57
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 29 · 2023: 17 · 2022: 18 · 2021: 18 · 2020: 6
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-06-22)
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- caffeine, Parkinson's disease, coffee consumption, disease risk, disease progression, dyskinesia, motor fluctuations, neuroprotection
- MeSH terms
- Caffeine, Coffee, Humans, Levodopa, Parkinson Disease, Cohort Studies, Proportional Hazards Models, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis. https://app.cochat.ai/papers/10.3390/nu12061860
- The paper
- Hong, C. T., Chan, L., & Bai, C.-H. (2020). The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis. Nutrients. https://doi.org/10.3390/nu12061860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.